Delivery Order SPE2DB20D9331-SPE2DB25FL1Z8
Award Date 9/15/25
Potential Completion Date 9/16/25
Potential Value $4.2K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- On August 1, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg tablets (120-count units). This firm fixed-price delivery order is associated with DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion contract vehicle valid through November 2026 that enables the agency to issue delivery orders for comprehensive...
- On June 18, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count unit). This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which carries a total value of $499,999,999 and remains valid through November 2026. The ultimate completion date for this delivery order is June 20, 2025,...
- On September 16, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $16,678.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order (4569478146) is for 120 tablets of Xtandi 40 mg, an oncology medication, with an ultimate completion date of September 17, 2025. This award was issued without a set-aside designation, leveraging DMS Pharmaceutical Group's competitive capabilities...
- On August 7, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, identified as 4569023499, is for 60 tablets of Xtandi 80 mg, an oncology medication. This award was issued without a set-aside designation and carries an ultimate completion date of August 8, 2025. The order represents a single delivery under DMS...
- The Defense Logistics Agency awarded a $4,169.59 delivery order to DMS Pharmaceutical Group Inc. on September 5, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, designated 4569340914, is scheduled for completion by September 8, 2025, and will be performed at the vendor's facility in Park Ridge, Illinois. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a...
- On August 11, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order covers 120 capsules of Xtandi 40 mg, an oncology treatment medication, under a firm fixed-price contract with an ultimate completion date of August 12, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- On September 16, 2025, the Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, an oral medication used in oncology treatment. This firm fixed-price delivery order, issued without a set-aside designation, represents a single issuance under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 through November 2026. The performance location is...
- On September 9, 2025, the Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count). This firm fixed-price delivery order represents a single shipment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.9 billion vehicle that enables the agency to procure a comprehensive range of pharmaceutical products for Department of Defense healthcare...
- On September 5, 2025, the Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $43,113.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order covers the supply of 120 capsules of Xtandi 40 mg, an oncology medication used in cancer treatment. This award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, which is...
- On September 8, 2025, the Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, valued at $8,622.72, carries a firm fixed-price structure with an ultimate completion date of September 9, 2025. The delivery order carries no set-aside designation and represents performance at the contractor's...